Use of full-length metallic stents in malignant ureteral obstruction.

INTRODUCTION Malignant ureteral obstruction (MUO) has traditionally been a difficult problem to manage. Indwelling ureteral stents have a failure rate up to 50%, necessitating the placement of percutaneous nephrostomy (PCN) drainage, which has associated complications and impacts on quality of life. Recently, metallic ureteral stents have emerged as a treatment for extrinsic ureteral obstruction. We present our initial experience using Resonance (Cook Urologic, Spencer, IN) full-length metallic stents for MUO. MATERIALS AND METHODS 20 patients (27 renal units) with advanced cancers and MUO were treated with metallic stents. Patients were followed prospectively to evaluate for recurrent obstruction. Perioperative morbidity and overall mortality were recorded. RESULTS The mean patient age was 49.9 years (SD 18.9). The primary malignancies causing MUO were gastrointestinal (8), gynecologic (6), genitourinary (2), or other (4). All but two renal units had been previously treated with traditional stents. Eight out of 20 (40%) patients required further intervention for their MUO. Mean time to failure for the metallic stents was 7.4 months (222 days). Two patients required conversion to percutaneous drainage. Five patients required change to traditional stents (3) or removal of metallic stents. At the last follow-up, sixteen patients had died. Fourteen of the sixteen patients died with functioning metallic stents in place, although one patient who initially had bilateral metallic stent placements had a left stent removed due to migration. Of the remaining four living patients, two have functioning metallic stents at a mean follow-up of 42 months. DISCUSSION MUO remains a difficult clinical problem in a group of patients with a high mortality. While metallic stents ultimately have a failure rate similar to that of traditional stents, the mean time to failure is longer. Therefore, metallic stents may benefit patients with MUO, because the longer dwell time may eliminate the need for more frequent stent changes or further interventions.

[1]  J. Stolzenburg,et al.  Ureteral obstruction: is the full metallic double-pigtail stent the way to go? , 2010, European urology.

[2]  U. Nagele,et al.  Initial clinical experience with full-length metal ureteral stents for obstructive ureteral stenosis , 2008, World Journal of Urology.

[3]  K. Loughlin,et al.  Cost of malignant ureteral obstruction treated with ureteral stents , 2007 .

[4]  Manoj Monga,et al.  Wire-based ureteral stents: impact on tensile strength and compression. , 2007, Urology.

[5]  L. Wong,et al.  Malignant ureteral obstruction: outcomes after intervention. Have things changed? , 2007, The Journal of urology.

[6]  J. Cartledge,et al.  Initial Experience with the Resonance Metallic Stent for Antegrade Ureteric Stenting , 2007, CardioVascular and Interventional Radiology.

[7]  R. Clayman,et al.  In-vivo evaluation of flow characteristics of novel metal ureteral stent. , 2007, Journal of endourology.

[8]  R. Clayman,et al.  Initial experience with full-length metal stent to relieve malignant ureteral obstruction. , 2006, Journal of endourology.

[9]  M. Monga,et al.  In vitro evaluation of ureteral stent compression. , 2006, Urology.

[10]  K. Loughlin,et al.  The management of malignant ureteral obstruction treated with ureteral stents. , 2005, The Journal of urology.

[11]  F. R. Romero,et al.  Indications for percutaneous nephrostomy in patients with obstructive uropathy due to malignant urogenital neoplasias. , 2005, International braz j urol : official journal of the Brazilian Society of Urology.

[12]  J. R. Wilson,et al.  The role of percutaneous nephrostomy in malignant ureteric obstruction. , 2005, Annals of the Royal College of Surgeons of England.

[13]  Douglas Landsittel,et al.  15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. , 2004, The Journal of urology.

[14]  G. Bellman,et al.  Management of ureteral obstruction secondary to pelvic malignancies. , 1999, Journal of endourology.

[15]  M. Banerjee,et al.  Outcome of palliative urinary diversion in the treatment of advanced malignancies , 1999, Cancer.

[16]  N. Clarke,et al.  Urinary tract obstruction and nephrostomy drainage in pelvic malignant disease. , 1995, British journal of urology.

[17]  K. Harrington,et al.  Palliation of obstructive nephropathy due to malignancy. , 1995, British journal of urology.

[18]  B. Fallon,et al.  Nephrostomy in cancer patients: to do or not to do? , 1980, British journal of urology.